E-mail a Wiley Online Library Link

C.A. Drukker, J.M. Bueno-de-Mesquita, V.P. Retèl, W.H. van Harten, H. van Tinteren, J. Wesseling, R.M.H. Roumen, M. Knauer, L.J. van 't Veer, G.S. Sonke, E.J.T. Rutgers, M.J. van de Vijver and S.C. Linn A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study International Journal of Cancer 133

Article first published online: 4 MAR 2013 | DOI: 10.1002/ijc.28082

What's new?

The “MammaPrint” is a 70-gene signature developed to predict the risk of breast cancer metastases. This study, the RASTER study, provides the first prospective data looking at this 70-gene signature to evaluate it's performance. For 427 patients, treatment decisions were based on standard guidelines, the 70-gene signature, and doctors' and patients' preferences. Here, 124 patients were categorized as “low-risk” by the 70-gene signature, but high-risk by other measures, such as age, tumor size, nodal status, and other clinicopathological factors. Of these, 76% did not receive adjuvant chemotherapy, and 98% survived 5 years with no recurrence of disease. Thus, withholding chemotherapy based on the low-risk gene signature result, and in accordance with doctors' and patients' preferences, did not negatively impact recurrence rate, confirming the prognostic value of this new tool.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field